What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - News Dr. Gabriela Guillén of Vall d'Hebron receives the award for best presentation at the LXI Congress of the SECP "Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR. News For the second year in a row, a research study from the Vall d'Hebron Urology Service has been recognised by the UB-HUB Chair of Robotic Surgery ABEX The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control. Activities Vall d'Hebron Talks 'ITS, què és important saber' Ponent : Dra. Maider Arando, especialista en medicina interna / infeccioses. Facultativa especialista a la Unitat d'ITS Vall d'Hebron-Drassanes des de l'any 2008. Doctora per la universitat de la UAB el 2019, la tesi va ser sobre sífilis. Resum: explicació sobre les ITS exsudatives (gon Activities Defensa de Tesi 'Noves dianes terapèutiques en sepsi' Doctorand: Luis Silvestre Chiscano Camón, grup de Recerca de Shock, Disfunció Orgànica i Ressucitació. Vall d'Hebrton Institut de Recerca (VHIR) Directors: Dr. Ricard Ferrer Roca i Dr. Juan Carlos Ruiz Rodríguez Tutor: Dr. Ricard Ferrer Roca News VHIR exceeds 700 active clinical trials to achieve new therapies for patients On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies. News Biomarkers gain prominence in paediatric cancer clinical trials A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress. News Vall d'Hebron boosts the search for new drugs for head and neck cancer The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor. Activities Vall d'Hebron Talks 'Angioedema Hereditari: Què és i com reconèixer-ho?' Ponent: Dra. Mar Guilarte Clavero, adjunta del Servei d'Al·lergologia. Coordinadora Centre de Referència CSUR d'Angioedema Hereditari. Hospital Universitari Vall d'Hebron. L'Angioedema Hereditari (AEH) és una malaltia minoritària, que sovint és desconeguda per molts professionals sanita Activities Symposium 'Career Day' Program: 09-00 – 09.10 Welcome to Career Day, Dr. Anna Santamaria Margalef, Internal Strategy Director, VHIR Activities Jornada del Dia Mundial del Lupus Programa 16.00h Presentació Dia Mundial del Lupus Sra. Maria Royo, investigadora i Coordinadora d'assajos clínics de la unitat Lupus-Reumatologia de la Vall d'Hebron Institut de Recerca. 16.15h Noves teràpies al Lupus Eritematós Sistèmic Dra. Josefina Cortés-Hern News Identified one of the mechanisms involved in the progression of Dent's disease to renal fibrosis Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation. Activities Vall d'Hebron Talks by VHIR 'Towards the utilization of cannabinoids as anticancer agents and other stories inspired by cannabis' Speaker: Dr. Guillermo Velasco Díez, deparment of Biochemistry and Molecular Biology, School of Biology, Complutense University. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040-Madrid. Spain A large body of evidence shows that cannabinoids, in additi News 1st Vall d'Hebron Ventures Summit El VHIR organitza la primera trobada entre emprenedors i l’ecosistema inversor. News Vall d'Hebron identifies a new therapeutic target for an aggressive childhood cancer affecting the muscles The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models. Activities Vall d’Hebron Ventures Summit 16:30h Benvinguda institucional 16:45h Presentacions companyies (1a part): Imidomics (Sara Marsal, CMO), Bsure M News The PHASE IV AI project organizes a session to evaluate the impact of artificial intelligence on lung cancer care The event, organized by Vall d'Hebron and Eurecat, has brought together health professionals and researchers in clinically applied AI to improve the medical care of patients. Activities Defensa de Tesi 'Avanç en les cures infermeres a les persones amb malaltia inflamatòria intestinal' Doctoranda: Ester Navarro Correal, grup de Recerca Multidisciplinari d'infermeria del Vall d'Hebron Institut de Recerca (VHIR) Directores: Dra. Laia Selva i Dra. Anna Espart Tutora: Dra. Anna Espart Enllaç Activities Vall d'Hebron Talks by VHIR 'iPSC- and CRISPR-based 3D brain tissue models recapitulate key features of neurodegenerative and neurovascular diseases' Speaker: Dr. Dominik Paquet, Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany Brain research heavily depends on models recapitulating key aspects of human brain physiology and disease pathology. Human iPSCs have great potential to comple Activities Vall d'Hebron Talks by VHIR 'Descripció funcionament procés d'Innovació VHIR' Presentació dels nous criteris multidimensionals que permeten fer un millor acompanyament als projectes d'Innovació segons el nivell de maduresa i les necessitats en cada etapa del procés. Ponents: Activities Actualizaciones y controversias en la monitorización de la PIC y de la presión de perfusión cerebral en el paciente neurocrítico Más información: https://aula.vallhebron.com/aula/?go=info_cursos&curso=660 Para cualquier otra información Pagination First page « Previous page ‹ … Page 17 Page 18 Current page 19 Page 20 Page 21 … Next page › Last page »
